Injectable NAD+ raises different questions compared to oral NR or NMN. Individuals looking for information on lyophilised NAD+ vials, compounding injection preparations, or ready-to-use pens often want to know what amounts have been used in published studies, how different vial strengths translate to concentration, what reconstitution is, how injectable preparations are generally administered, and how prepared solutions are stored. However, there is a significant gap in the available evidence. Most injectable NAD+ preparations currently available are compounded or research-use products, rather than FDA- or EMA-approved medicines supplied with a single standardised, regulatory-verified dosing and preparation protocol.
Therefore, there is no single universal injection dose of NAD+, reconstitution ratio, administration frequency, or post-reconstitution shelf life that can be safely applied to every product.
Available human studies are also much more limited than the current commercial market might suggest.
Published research has focused primarily on the intravenous administration of NAD+ in supervised clinical settings. By contrast, controlled data regarding self-administered subcutaneous NAD+, intramuscular NAD+ and commercial NAD+ pens remain very limited.
Therefore, this guide focuses on what has actually been used in published research. It also explains the basic pharmaceutical principles regarding injectable NAD+ formulations and separates research findings from commercial and online community protocols.
Specific product instructions provided by a doctor or the pharmacy preparing a compounded medicine should always take precedence. This is because the concentration, excipients, sterility requirements, stability and the formulation itself can vary significantly between preparations.
NAD+ injection dosage chart: what was actually researched?
In published studies involving humans, very different doses of NAD+ have been used, depending on the specific clinical context.
This is one of the reasons why the size of a commercial vial should never be interpreted as a verified dose.
In one controlled clinical trial, a relatively small daily amount of intravenous NAD+ was used.
In contrast, a retrospective analysis of the real-world use of commercial IV therapy involved a significantly larger quantity.
Commercial vials, on the other hand, may contain significantly more NAD+ than a single dose used in any of these studies.
| Context | Applied dose | Frequency | Duration | Application route |
|---|---|---|---|---|
| Randomised placebo-controlled trial in patients with heart failure/haemolytic cardiomyopathy [1] | 10 mg/day | Once a day | 7 days | Intravenously |
| Retrospective study of the real-world tolerability of commercial IV therapy [2] | 500 mg/day | Once a day | 4 consecutive days | Intravenously |
| Typical commercial vial sizes, not verified clinical doses | 100 mg, 500 mg or 1000 mg per vial | Depending on the product/protocol | Depending on the product/protocol | They can be offered for subcutaneous, intramuscular or intravenous administration |
The differences are immediately apparent.
A randomised clinical trial used 10 mg daily.
However, in a retrospectively analysed commercial intravenous use, 500 mg per day was administered, which is fifty times more than the daily amount used in the controlled heart failure study. [1,2]
None of these values should be automatically regarded as the correct dose for another application.
The populations, objectives, formulations, administration conditions and study designs were different.
Commercial vial sizes are another source of confusion.
The vial containing 500 mg or 1000 mg describes the total nominal amount of substance contained in the pack.
This does not mean that the whole vial constitutes a single dose.
It also does not specify what the final concentration of the preparation should be, how often it should be administered, or whether the given quantity has been verified for subcutaneous or intramuscular administration.
Most importantly, controlled human studies have not established a standardised protocol for the self-administration of subcutaneous NAD+ using commercial pens or reconstituted vials.
Therefore, the NAD+ dosage charts available online generally reflect the practices of individual doctors, compounding pharmacies, manufacturer instructions, or user habits, rather than a single clinically verified regimen.
What does subcutaneous administration of NAD+ mean?
A subcutaneous injection means the administration of a medicinal product or preparation into the layer of fatty tissue located beneath the skin, rather than directly into a vein or muscle.
This is a well-established route of administration for many approved medicines.
However, the existence of standard subcutaneous injection techniques does not mean that a specific NAD+ formulation has been clinically verified for this route of administration.
This distinction is important.
Most published research concerning NAD+ injections utilised supervised intravenous administration.
Controlled studies directly evaluating self-administered subcutaneous NAD+ remain scarce.
Subcutaneous preparations may also differ in concentration, excipients, pH, sterility requirements and device design.
Therefore, the correct administration technique, permitted injection sites, volume, type of device and dose should be based on the instructions of a doctor, pharmacist or the manufacturer responsible for the specific formulation, rather than a general protocol concerning NAD+.
The basic safety rules regarding medicines administered by injection still apply.
Hands, equipment and the site of administration should be maintained under appropriate hygienic conditions.
With repeated subcutaneous injections, rotation of the injection sites is usually necessary if this method of administration has been recommended.
Single-use needles should not be reused.
Used needles and other sharp objects require proper disposal.
A solution that has unexpectedly become cloudy, changed colour, appears contaminated or contains visible particles should not automatically be considered suitable for use.
These are general principles concerning injectable medicines, not evidence specific to NAD+.
Any person who has not previously used the prescribed self-injection medicine should receive practical instruction from an appropriately qualified healthcare professional or pharmacist before attempting self-administration.
What does NAD+ reconstitution with bacteriostatic water mean?
Reconstitution means the conversion of a lyophilised, i.e. freeze-dried, powder into a liquid preparation using a specified sterile solvent.
This is not a process exclusive to NAD+.
Many pharmaceutical preparations for injection are stored as a dry powder, as this state can ensure greater stability than the continuous storage of the active substance dissolved in water.
Bacteriostatic water is one of the possible solvents used in the case of certain multi-dose injectable preparations.
It contains sterile water and a small amount of benzyl alcohol, the purpose of which is to limit microbial growth after repeated piercing of the vial.
However, this does not mean that bacteriostatic water is suitable for every NAD+ preparation.
The correct solvent depends on the specific formulation.
Some compounded preparations may require sterile water, bacteriostatic water, saline, another vehicle or a solvent system specially prepared by the pharmacy.
Why does the volume used for reconstitution matter?
The amount of solvent affects the concentration of the final solution.
The basic relationship is simple:
final concentration = total amount of NAD+ in the vial ÷ final volume of the liquid.
The more concentrated preparation contains more NAD+ per millilitre.
The more diluted preparation contains less NAD+ in one millilitre.
The total nominal amount of NAD+ originally present in the vial does not change simply because a larger or smaller amount of solvent is used.
However, this basic calculation should not be treated as a recommendation for the preparation of the medicinal product.
A change in concentration may also affect the injection volume, tolerability, pH-related properties, device compatibility and potentially stability.
Therefore, the choice of reconstitution volume is not purely a mathematical exercise.
It should be used in accordance with the instructions for that particular formulation, as provided by the pharmacy dispensing the prescription or the manufacturer.
Why is there no universal NAD+ reconstitution ratio?
Commercial NAD+ supplements vary from one another.
Two vials labelled with the same number of milligrams may differ in purity, excipients, chemical form, required pH, intended route of administration and concentration specification.
Scientific literature also does not specify a single, universally verified ratio of bacteriostatic water to NAD+ for the commonly sold 100 mg, 500 mg or 1000 mg vials intended for self-injection.
The general principles of pharmacy therefore explain what reconstitution involves.
However, they do not establish a universal formula.
The prepared solution for injection should meet the requirements specified for the particular formulation.
If instructions are missing or unclear, the correct course of action is to obtain information from the dispensing pharmacy or a suitably qualified healthcare professional, rather than using general proportions found on the internet.
NAD+ pens: what are they and how do they differ from vials?
Peny NAD+ are injection devices designed to make repeated subcutaneous administration more convenient.
Some products are supplied pre-filled.
Others use replaceable cartridges.
Depending on the design, the user can select the quantity using a dial, a numbered setting or a click-based mechanism.
This form can reduce some of the manual tasks associated with traditional multidose vials.
However, NAD+ levels are not standardised across manufacturers.
The delivered dose per click, cartridge concentration, needle compatibility, method of pen preparation before use, storage conditions and shelf life after opening may vary.
Therefore, a setting used on one pen cannot automatically be interpreted in the same way on another device.
Pens used to administer well-known medications, such as insulin or GLP-1 receptor agonists, undergo extensive device-specific validation.
Commercial NAD+ products do not necessarily have a comparable body of evidence verified by regulatory authorities.
For this reason, the specific pen's instructions remain crucial.
General rules for using pens include using the device exclusively with compatible sterile components, checking the selected dose before administration, rotating injection sites for repeated subcutaneous injections if recommended, and storing the device in accordance with the requirements of the specific formulation.
This is merely general information.
They do not replace device-specific instructions or professional training.
How long can NAD+ be stored after reconstitution?
A freeze-dried compound may behave differently once reconstituted.
After adding water, a few new stability issues arise.
Chemical degradation may occur.
Oxidation or hydrolysis processes may become more significant.
Repeated vial puncture introduces additional microbiological considerations.
Temperature and exposure to light may also affect some formulations.
Because of this, reconstituted injection preparations usually have a specified shelf-life after preparation.
In the case of many multi-dose pharmaceutical preparations containing bacteriostatic water, storage periods of approximately two to four weeks can be encountered in general compounding practice. [3]
However, this range should not be treated as a verified shelf-life of NAD+.
The number of published studies precisely determining how long a specific reconstituted NAD+ preparation maintains adequate chemical activity, sterility, purity and an acceptable level of degradation products is limited.
Individual formulations may therefore have different use-by dates once prepared.
Storing in the fridge
Many reconstituted injectable preparations require refrigeration.
This rule is also frequently applied in the case of compounded NAD+ preparations.
However, the required temperature range should be determined by the product-specific instructions.
The product should not automatically be stored in a fridge, frozen, or repeatedly moved between different temperatures solely on the basis of assumptions concerning peptides or other substances for injection.
NAD+ itself is not a peptide, and stability requirements should be determined for the specific formulation.
Exposure to light
For some compounded preparations, protection against excessive exposure to light may also be recommended.
Once again, this depends on the stability data for the specific formulation.
The original packaging and container supplied by the pharmacy are usually designed to suit the specified storage conditions.
Recording the date of preparation
For each reconstituted multi-dose product, it is important to record the date of preparation or first use accurately.
This helps to prevent the use of a multi-dose vial after the expiry date specified by the pharmacy or the manufacturer.
Changes in the appearance of the solution
Unexpected cloudiness, discolouration, the formation of a precipitate, visible particles, damaged packaging or suspected contamination are warning signs.
The normal appearance of the solution does not guarantee its sterility or chemical stability.
Similarly, you should not ignore the fact that the expiry date has passed after preparation simply because the liquid is still clear.
Storage instructions provided by the pharmacy or manufacturer remain a more reliable standard.
How often was NAD+ used in injections in the studies?
The frequency of administration is another area in which clinical trials and commercial practice differ significantly.
The available controlled human studies have generally involved short periods of daily administration.
In a randomised trial on heart failure, NAD+ was administered intravenously once daily for seven days at a dose of 10 mg per day. [1]
In a retrospective analysis of commercial IV use, participants received 500 mg daily for four consecutive days. [2]
These protocols addressed specific research questions.
They do not establish a universal long-term regimen for the use of NAD+.
None of these studies determined whether weekly injections, administration every other day, long-term maintenance treatment or repeated monthly cycles were more effective.
Controlled clinical trials have also failed to establish a single validated regimen for subcutaneous maintenance therapy.
Commercial self-administration protocols may involve daily use, alternate-day use, several times a week or according to other cyclic schedules.
These schemes must be clearly distinguished from the protocols used in published studies.
They usually stem from product leaflets, the practices of compounding pharmacies, individual doctors’ recommendations or users’ habits.
At present, there is insufficient evidence to conclude that any one of these regimens provides better exposure to NAD+, more favourable clinical outcomes or greater long-term safety.
Total exposure is also important.
A smaller dose given more frequently and a larger dose given less frequently are not automatically equivalent.
In the absence of pharmacokinetic data relating to a specific route of administration and formulation, a simple comparison of the total weekly dose in milligrams is not sufficient to establish bioequivalence.
Therefore, the frequency, dose, formulation and route of administration should be considered collectively, rather than as separate, interchangeable variables.
Comparison of evidence regarding different routes of NAD+ administration
| Question | NAD+ intravenously | NAD+ subcutaneously | NAD+ intramuscularly | Peny NAD+ |
|---|---|---|---|---|
| Published human experiments | Yes | Limited | Limited | Very limited |
| Controlled dose studies | Some, under specific clinical conditions [1] | Insufficiently established | Insufficiently established | Lack of standardisation as a category |
| Commercial availability | Yes | Yes | Yes | Yes |
| Universal, standardised dose | Not | Not | Not | Not |
| Standardised reconstitution protocol | Formulation-dependent | Formulation-dependent | Formulation-dependent | Usually device/formulation dependent |
| Data regarding long-term, repeated use | Limited | Very limited | Very limited | Very limited |
| Proven direct anti-ageing/wellness efficacy | Not | Not | Not | Not |
The most important conclusion is that commercial availability is much wider than the scope of clinical validation.
Frequently asked questions about the dosage and reconstitution of injectable NAD+
What is the typical NAD+ injection dose?
There is no single, universally verified dose of NAD+ for injection. Published human studies have used widely varying intravenous amounts, including 10 mg daily for seven days in one randomised trial of heart failure and 500 mg daily for four consecutive days in a retrospectively analysed commercial IV use. [1,2]
These protocols should not be interpreted as standardised doses of NAD+ for subcutaneous or intramuscular use, wellness purposes, or self-administration.
Does a 500 mg NAD+ vial mean a 500 mg dose?
No.
A 500 mg vial specifies the nominal total amount of NAD+ contained within the vial.
It does not specify the amount intended for a single administration, the final concentration after preparation, the frequency of use, or an evidence-based treatment regimen.
Is the 1000 mg NAD+ vial stronger than the 500 mg vial?
The 1000 mg vial contains twice the nominal total mass of NAD+ as the 500 mg vial, but this does not automatically mean that a single administration will be „stronger”.
The final concentration and the actual amount administered depend on the method of preparation and the instructions for the specific product.
How much bacteriostatic water should be added to NAD+?
There is no single verified volume suitable for every NAD+ vial.
The appropriate solvent and final concentration depend on the specific compounding formulation, the amount in the vial, the intended route of administration, the excipients, and the pharmacy instructions.
Reconstitution should therefore be carried out in accordance with the instructions provided with the specific product, rather than based on a universal ratio found on the internet.
Can NAD+ be reconstituted with bacteriostatic water?
Some compounding preparations may require bacteriostatic water, whilst others may require another sterile diluent.
You should not automatically assume that bacteriostatic water is appropriate just because the product is supplied as a lyophilised powder.
Does adding more water change the amount of NAD+?
Adding more solvent changes the concentration, not the total nominal amount of NAD+ originally in the vial.
The more diluted preparation contains fewer milligrams per millilitre, whereas the more concentrated one contains more milligrams per millilitre. The appropriate concentration should, however, be based on the instructions for the specific product.
Can NAD+ be administered subcutaneously?
NAD+ preparations intended for subcutaneous administration are commercially available, but controlled human studies regarding standardised subcutaneous dosing, pharmacokinetics, frequency of use and long-term safety are considerably more limited than the literature on supervised intravenous administration.
The commercial preparation should therefore be used solely in accordance with its specific medical or pharmaceutical instructions.
Is intramuscular NAD+ better than subcutaneous NAD+?
Currently, there are no robust controlled human studies confirming the superiority of intramuscular NAD+ over subcutaneous NAD+.
There is a lack of direct studies comparing the pharmacokinetics and outcomes for these two routes of administration.
How long can NAD+ be stored after reconstitution?
A single universal shelf-life for reconstituted NAD+ has not been established in the published literature.
General sources on multi-dose preparations sometimes give shelf-lives counted in weeks, but the exact period depends on the specific formulation, diluent, sterility conditions, container and stability data provided by the pharmacy or manufacturer. [3]
Should reconstituted NAD+ be stored in the fridge?
Many compounded NAD+ preparations are supplied with the recommendation to store them in the fridge after reconstitution.
However, the exact requirements should stem from the instructions for the specific product or pharmacy.
Storage conditions should not be generalised to all formulations.
Can NAD+ be used every day?
Daily intravenous administration for short periods was used in human studies. [1,2]
However, this does not confirm the safety or efficacy of long-term, daily use of NAD+ subcutaneously, intramuscularly, or via a pen.
The long-term frequency of use remains insufficiently understood.
Limitations of current research
The biggest limitation is that published research on NAD+ injections does not accurately reflect a large portion of the modern commercial market.
Controlled human studies have primarily involved supervised intravenous administration.
Self-administered subcutaneous preparations, injection pens, and commercial dosing regimens have not been studied in an equally rigorous manner.
The second limitation is the huge difference between the quantities tested.
In one randomised trial, 10 mg daily was used.
However, a retrospective study of commercial IV use evaluated 500 mg daily. [1,2]
These values cannot simply be placed on a single universal dose–response scale because the studies involved different populations, objectives, designs and clinical conditions.
Reconstitution represents another significant gap in the evidence.
Scientific literature does not specify a single standardised amount of bacteriostatic water for commonly sold NAD+ vials of various strengths.
General concentration calculations can explain how dilution works, but they do not make it possible to determine what concentration is appropriate for a specific compounded preparation.
Similar uncertainty applies to the stability after reconstitution.
General pharmaceutical sources outline the principles for handling reconstituted multidose preparations, but the number of peer-reviewed NAD+ stability studies allowing for the establishment of a single universal storage period remains limited. [3]
Commercial pens introduce additional volatility.
Individual devices may contain different concentrations and deliver varying amounts at a specific setting or click.
Therefore, one should not assume the existence of a universal conversion factor for pens.
Long-term safety also remains insufficiently understood.
Short periods of supervised treatment do not allow the effects of repeated subcutaneous or intramuscular administration over many months or years to be determined.
Finally, commercial application should not be equated with clinical validation.
The availability of 100 mg, 500 mg or 1000 mg vials, injection pens or repeated clinical protocols shows that such products exist on the market.
It does not, however, prove that specific potencies, regimens or routes of administration have been confirmed as optimal in randomised controlled trials.
Disclaimer
This article is for educational and scientific-information purposes only. It does not constitute medical advice, a prescription, individual dosage recommendations, reconstitution instructions, injection training, or a recommendation for the use of NAD+ in injection form.
The doses discussed above describe the amounts used in specific published studies and should not be interpreted as standardised, approved or suitable for self-administration. Injectable NAD+ preparations are not approved by the FDA or EMA for anti-ageing, wellness, energy-boosting or the prevention or treatment of diseases.
Compounded NAD+ preparations may vary in concentration, required solvent, excipients, sterility requirements, storage conditions, device design and expiry date. Reconstitution and administration should therefore take place in accordance with the instructions provided by the attending physician, the authorised pharmacy preparing the compounded medicine, or the manufacturer responsible for the specific formulation. Incorrect preparation or administration of the injection may lead to contamination of the preparation, infection, tissue damage, dosage errors or other complications.
References
[1] American Journal of Cardiovascular Drugs. (2026). Effect of nicotinamide adenine dinucleotide on heart failure caused by ischaemic cardiomyopathy: A randomised, placebo-controlled trial. American Journal of Cardiovascular Drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12779688/
[2] Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582
[3] Empower Pharmacy. (2025). How to prepare a lyophilised powder for injection. Empower Pharmacy Patient Resources. https://www.empowerpharmacy.com/compound-medication/medication-instructions/how-to-prepare-lyophilized-powder-for-injection/